selective calcium channel blockers	inhibit	L‑type calcium channels
L‑type calcium channels	mediate	cardiac contraction
selective calcium channel blockers	reduce	myocardial oxygen demand
myocardial oxygen demand	lowers	angina frequency
selective calcium channel blockers	decrease	heart rate
heart rate	reduces	cardiac workload
selective calcium channel blockers	lower	blood pressure
blood pressure	decreases	stroke volume
stroke volume	reduces	cardiac output
cardiac output	improves	exercise tolerance
selective calcium channel blockers	improve	left ventricular function
left ventricular function	enhances	ejection fraction
ejection fraction	predicts	heart failure prognosis
selective calcium channel blockers	prevent	ventricular arrhythmias
ventricular arrhythmias	reduce	sudden cardiac death
selective calcium channel blockers	treat	hypertension
hypertension	associated with	renal failure
selective calcium channel blockers	protect	kidneys
kidneys	maintain	electrolyte balance
electrolyte balance	influences	arrhythmia risk
selective calcium channel blockers	cause	peripheral edema
peripheral edema	indicates	fluid overload
fluid overload	predicts	readmission risk
selective calcium channel blockers	improve	diastolic function
diastolic function	correlates with	diastolic heart failure
diastolic heart failure	linked to	mortality
selective calcium channel blockers	reduce	myocardial infarction risk
myocardial infarction	increases	mortality
selective calcium channel blockers	lower	coronary artery spasm
coronary artery spasm	causes	Prinzmetal angina
Prinzmetal angina	treated by	calcium channel blockers
selective calcium channel blockers	improve	exercise capacity
exercise capacity	predicts	long‑term survival
selective calcium channel blockers	reduce	left atrial size
left atrial size	associated with	atrial fibrillation
atrial fibrillation	increases	stroke risk
selective calcium channel blockers	lower	pulmonary hypertension
pulmonary hypertension	predicts	right heart failure
right heart failure	leads to	mortality
selective calcium channel blockers	decrease	QT interval
QT interval	influences	torsades de pointes risk
torsades de pointes	causes	sudden death
selective calcium channel blockers	improve	quality of life
quality of life	correlates with	adherence
adherence	predicts	hospitalization rate
selective calcium channel blockers	contraindicated in	severe aortic stenosis
severe aortic stenosis	associated with	poor outcomes
selective calcium channel blockers	interact with	beta‑blockers
beta‑blockers	used in	heart failure
heart failure	requires	diuretic therapy
diuretic therapy	manages	fluid status
fluid status	affects	renal function
renal function	predicts	drug clearance
drug clearance	determines	dosing schedule
dosing schedule	influences	side‑effect profile
side‑effect profile	impacts	patient satisfaction
patient satisfaction	drives	medication persistence
medication persistence	reduces	readmission
readmission	increases	healthcare cost
healthcare cost	limits	resource allocation
resource allocation	affects	treatment availability
treatment availability	determines	clinical outcomes
clinical outcomes	measured by	composite endpoints
composite endpoints	include	mortality	rehospitalization	symptom burden
mortality	is a key	endpoint
rehospitalization	is a key	endpoint
symptom burden	assessed by	NYHA class
NYHA class	predicts	survival
selective calcium channel blockers	reduce	myocardial calcium influx
myocardial calcium influx	lowers	intracellular calcium overload
intracellular calcium overload	prevents	cell death
cell death	leads to	myocardial remodeling
myocardial remodeling	worsens	heart failure
heart failure	increases	mortality
selective calcium channel blockers	improve	coronary vasodilation
coronary vasodilation	enhances	myocardial perfusion
myocardial perfusion	reduces	ischemic episodes
ischemic episodes	lower	arrhythmia burden
arrhythmia burden	reduces	sudden death
sudden death	is a major	cause of mortality
selective calcium channel blockers	are metabolized by	CYP3A4
CYP3A4	inhibited by	macrolide antibiotics
macrolide antibiotics	increase	drug levels
drug levels	raise	toxicity risk
toxicity risk	leads to	adverse events
adverse events	cause	discontinuation
discontinuation	results in	uncontrolled hypertension
uncontrolled hypertension	elevates	cardiovascular risk
cardiovascular risk	predicts	long‑term mortality
selective calcium channel blockers	have	drug‑drug interaction profile
drug‑drug interaction profile	informs	prescribing decisions
prescribing decisions	affect	patient safety
patient safety	measured by	adverse event rate
adverse event rate	correlates with	readmission
readmission	is a target	quality metric
quality metric	influences	reimbursement
reimbursement	determines	drug availability
drug availability	impacts	treatment choice
treatment choice	influences	clinical outcomes
clinical outcomes	guide	guideline updates
